Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06301945

Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors

Artificial Intelligence for Histopathological Classification and Recurrence Prediction of Thymic Epithelial Tumors

Status
Recruiting
Phase
Study type
Observational
Enrollment
1,020 (estimated)
Sponsor
Erasmus Medical Center · Academic / Other
Sex
All
Age
Healthy volunteers

Summary

Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection. Administration of postoperative radiotherapy is usually indicated in patients with more extensive local disease, incomplete resection and/or more aggressive subtypes, defined by the WHO histopathological classification. In this classification thymoma types A, AB, B1, B2, B3, and thymic carcinoma are distinguished. Studies have shown large discordances between pathologists in subtyping these tumors. Moreover, the WHO classification alone does not accurately predict the risk of recurrence, as within subtypes patients have divergent prognoses. The investigators will develop AI models using digital pathology and relevant clinical variables to improve the accuracy of histopathological classification of thymic epithelial tumors, and to better predict the risk of recurrence. In this multicentric and international project three existing databases will be used from Rotterdam, Maastricht and Lyon. For all models one database will be used to build AI models, and the other two for external validation. The ultimate goal of this project is to develop AI models that support the pathologist in correctly subtyping thymic epithelial tumors, in order to prevent patients from under- or overtreatment with adjuvant radiotherapy.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTArtificial Intelligence DiagnosticsAI Diagnostics uses advanced algorithms for precise histological image analysis to help diagnose disease, including subtype.
DIAGNOSTIC_TESTRecurrence Prediction ToolThis AI tool evaluates thymic tumour data and other clinical data and calculates the risk of recurrence, with the aim of analysing whether there is an association with specific subtypes of thymic epithelial tumours and clinical data.

Timeline

Start date
2023-08-01
Primary completion
2027-08-01
Completion
2027-08-01
First posted
2024-03-08
Last updated
2024-03-27

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT06301945. Inclusion in this directory is not an endorsement.